FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for The FDA just announced that they're taking steps to lift restrictions on 12 peptides including BPC 157 and TB 500 making them accessible through compounding pharmacies again. This is a HUGE step The Peptide Craze Ground Truths FDA's Overreach on Compounded Peptides FDA Compliance for Peptide Therapy and BPC 157 Holt Law